ATG5 and osteosarcoma: Taken together, these data indicated that anlotinib treatment induced ATG5-dependent autophagy and that inhibition of autophagy enhanced the inhibitory effects of anlotinib on osteosarcoma metastasis through EMT and the RhoA-ROCK-LIMK2 pathway.